Last reviewed · How we verify

Venlafaxine XR — Competitive Intelligence Brief

Venlafaxine XR (Venlafaxine XR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin-norepinephrine reuptake inhibitor (SNRI). Area: Psychiatry / Mental Health.

marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT); Norepinephrine transporter (NET) Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Venlafaxine XR (Venlafaxine XR) — Ministry of Health & Welfare, Korea. Venlafaxine XR inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Venlafaxine XR TARGET Venlafaxine XR Ministry of Health & Welfare, Korea marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT); Norepinephrine transporter (NET)
Pristiq Desvenlafaxine Succinate Pfizer marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin and norepinephrine reuptake 2008-01-01
Effexor Venlafaxine Hydrochloride Pfizer marketed Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Serotonin and norepinephrine reuptake transporters 1993-01-01
Venlafaxine IR and Venlafaxine XR Venlafaxine IR and Venlafaxine XR North Dakota State University marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT) and norepinephrine transporter (NET)
desvenlafaxine succinate sustained release desvenlafaxine succinate sustained release Pfizer marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT) and norepinephrine transporter (NET)
toludesvenlafaxine hydrochloride sustained-release tablets toludesvenlafaxine hydrochloride sustained-release tablets Shanghai Mental Health Center marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT) and norepinephrine transporter (NET)
venlafaxine (Effexor) venlafaxine (Effexor) National Institute of Mental Health (NIMH) marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT, weak)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin-norepinephrine reuptake inhibitor (SNRI) class)

  1. Pfizer · 3 drugs in this class
  2. Wyeth is now a wholly owned subsidiary of Pfizer · 3 drugs in this class
  3. National Institute of Mental Health (NIMH) · 2 drugs in this class
  4. Zhejiang Huahai Pharmaceutical Co., Ltd. · 2 drugs in this class
  5. Eli Lilly and Company · 2 drugs in this class
  6. New York State Psychiatric Institute · 1 drug in this class
  7. North Dakota State University · 1 drug in this class
  8. Ministry of Health & Welfare, Korea · 1 drug in this class
  9. Purdue Pharma, Canada · 1 drug in this class
  10. Shanghai Mental Health Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Venlafaxine XR — Competitive Intelligence Brief. https://druglandscape.com/ci/venlafaxine-xr. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: